Bi‐allelic loss‐of‐function GALNT3 mutations alter FGF23 metabolism, resulting in hyperphosphatemia and causing familial tumoral calcinosis (FTC). This evidence concerns the gene GALNT3 and thyroid cancer, nonmedullary, 2.